Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays

Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Kazuhiro Toyoda, Kunimitsu Eiraku, Motohiro Shimizu, Yuji Harada, Fujiko Mitsumoto, Koji Takayama, Kyoko Okada, Mosaburo Kainuma, Jun Hayashi

研究成果: ジャーナルへの寄稿記事

19 引用 (Scopus)

抄録

Monitoring hepatitis C virus (HCV) kinetics during antiviral treatment is recommended for determining the best form of treatment management. We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12. weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients. The viral kinetics of 65 patients with HCV genotype 1b was assessed. HCV RNA was tested at baseline, on day 3, and every week from 1 to 12 by both the first-generation Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV (CAP/CTM) assay and the Abbott RealTime HCV (ART) assay. A total of 910 serum samples were obtained from the 65 patients. Of these, 168 (28.5%) of the 590 samples HCV RNA negative by CAP/CTM were positive by ART. In contrast, 17 (3.9%) of the 439 samples HCV RNA negative by ART were positive by CAP/CTM. The rates of HCV RNA negativity by ART at weeks 3, 4, and 5 were significantly lower than those by CAP/CTM (21.5% vs. 50.8%, 36.9% vs. 70.8% and 44.6% vs. 81.5%; P<. 0.001, P<. 0.0001 and P<. 0.05, respectively). Although the ART is superior for the determination of HCV RNA negativity, the predictive value of detectable HCV RNA for non-sustained virological response (non-SVR) by CAP/CTM is higher than by ART at weeks 4, 6, and 8. We also found that 16 (24.6%) by CAP/CTM and 28 (43.1%) by ART had a reappearance of residual HCV RNA during the telaprevir treatment period. However, the reappearance of residual HCV RNA was not associated with non-SVR. In conclusion, a significant difference was found between the two real-time PCR assays for the assessment of virological response based on undetectable HCV RNA.

元の言語英語
ページ(範囲)119-124
ページ数6
ジャーナルAntiviral Research
99
発行部数2
DOI
出版物ステータス出版済み - 8 1 2013

Fingerprint

Chronic Hepatitis C
Hepacivirus
Real-Time Polymerase Chain Reaction
RNA
Therapeutics
telaprevir
Ribavirin
Interferons
Antiviral Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

これを引用

Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy : A comparison of two real-time PCR assays. / Ogawa, Eiichi; Furusyo, Norihiro; Masayuki, Murata; Toyoda, Kazuhiro; Eiraku, Kunimitsu; Shimizu, Motohiro; Harada, Yuji; Mitsumoto, Fujiko; Takayama, Koji; Okada, Kyoko; Kainuma, Mosaburo; Hayashi, Jun.

:: Antiviral Research, 巻 99, 番号 2, 01.08.2013, p. 119-124.

研究成果: ジャーナルへの寄稿記事

Ogawa, Eiichi ; Furusyo, Norihiro ; Masayuki, Murata ; Toyoda, Kazuhiro ; Eiraku, Kunimitsu ; Shimizu, Motohiro ; Harada, Yuji ; Mitsumoto, Fujiko ; Takayama, Koji ; Okada, Kyoko ; Kainuma, Mosaburo ; Hayashi, Jun. / Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy : A comparison of two real-time PCR assays. :: Antiviral Research. 2013 ; 巻 99, 番号 2. pp. 119-124.
@article{b36390dd740b4f5aa1e384294b0d9319,
title = "Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays",
abstract = "Monitoring hepatitis C virus (HCV) kinetics during antiviral treatment is recommended for determining the best form of treatment management. We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12. weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients. The viral kinetics of 65 patients with HCV genotype 1b was assessed. HCV RNA was tested at baseline, on day 3, and every week from 1 to 12 by both the first-generation Roche COBAS{\circledR} AmpliPrep/COBAS{\circledR} TaqMan{\circledR} HCV (CAP/CTM) assay and the Abbott RealTime HCV (ART) assay. A total of 910 serum samples were obtained from the 65 patients. Of these, 168 (28.5{\%}) of the 590 samples HCV RNA negative by CAP/CTM were positive by ART. In contrast, 17 (3.9{\%}) of the 439 samples HCV RNA negative by ART were positive by CAP/CTM. The rates of HCV RNA negativity by ART at weeks 3, 4, and 5 were significantly lower than those by CAP/CTM (21.5{\%} vs. 50.8{\%}, 36.9{\%} vs. 70.8{\%} and 44.6{\%} vs. 81.5{\%}; P<. 0.001, P<. 0.0001 and P<. 0.05, respectively). Although the ART is superior for the determination of HCV RNA negativity, the predictive value of detectable HCV RNA for non-sustained virological response (non-SVR) by CAP/CTM is higher than by ART at weeks 4, 6, and 8. We also found that 16 (24.6{\%}) by CAP/CTM and 28 (43.1{\%}) by ART had a reappearance of residual HCV RNA during the telaprevir treatment period. However, the reappearance of residual HCV RNA was not associated with non-SVR. In conclusion, a significant difference was found between the two real-time PCR assays for the assessment of virological response based on undetectable HCV RNA.",
author = "Eiichi Ogawa and Norihiro Furusyo and Murata Masayuki and Kazuhiro Toyoda and Kunimitsu Eiraku and Motohiro Shimizu and Yuji Harada and Fujiko Mitsumoto and Koji Takayama and Kyoko Okada and Mosaburo Kainuma and Jun Hayashi",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.antiviral.2013.05.002",
language = "English",
volume = "99",
pages = "119--124",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy

T2 - A comparison of two real-time PCR assays

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Masayuki, Murata

AU - Toyoda, Kazuhiro

AU - Eiraku, Kunimitsu

AU - Shimizu, Motohiro

AU - Harada, Yuji

AU - Mitsumoto, Fujiko

AU - Takayama, Koji

AU - Okada, Kyoko

AU - Kainuma, Mosaburo

AU - Hayashi, Jun

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Monitoring hepatitis C virus (HCV) kinetics during antiviral treatment is recommended for determining the best form of treatment management. We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12. weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients. The viral kinetics of 65 patients with HCV genotype 1b was assessed. HCV RNA was tested at baseline, on day 3, and every week from 1 to 12 by both the first-generation Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV (CAP/CTM) assay and the Abbott RealTime HCV (ART) assay. A total of 910 serum samples were obtained from the 65 patients. Of these, 168 (28.5%) of the 590 samples HCV RNA negative by CAP/CTM were positive by ART. In contrast, 17 (3.9%) of the 439 samples HCV RNA negative by ART were positive by CAP/CTM. The rates of HCV RNA negativity by ART at weeks 3, 4, and 5 were significantly lower than those by CAP/CTM (21.5% vs. 50.8%, 36.9% vs. 70.8% and 44.6% vs. 81.5%; P<. 0.001, P<. 0.0001 and P<. 0.05, respectively). Although the ART is superior for the determination of HCV RNA negativity, the predictive value of detectable HCV RNA for non-sustained virological response (non-SVR) by CAP/CTM is higher than by ART at weeks 4, 6, and 8. We also found that 16 (24.6%) by CAP/CTM and 28 (43.1%) by ART had a reappearance of residual HCV RNA during the telaprevir treatment period. However, the reappearance of residual HCV RNA was not associated with non-SVR. In conclusion, a significant difference was found between the two real-time PCR assays for the assessment of virological response based on undetectable HCV RNA.

AB - Monitoring hepatitis C virus (HCV) kinetics during antiviral treatment is recommended for determining the best form of treatment management. We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12. weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients. The viral kinetics of 65 patients with HCV genotype 1b was assessed. HCV RNA was tested at baseline, on day 3, and every week from 1 to 12 by both the first-generation Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV (CAP/CTM) assay and the Abbott RealTime HCV (ART) assay. A total of 910 serum samples were obtained from the 65 patients. Of these, 168 (28.5%) of the 590 samples HCV RNA negative by CAP/CTM were positive by ART. In contrast, 17 (3.9%) of the 439 samples HCV RNA negative by ART were positive by CAP/CTM. The rates of HCV RNA negativity by ART at weeks 3, 4, and 5 were significantly lower than those by CAP/CTM (21.5% vs. 50.8%, 36.9% vs. 70.8% and 44.6% vs. 81.5%; P<. 0.001, P<. 0.0001 and P<. 0.05, respectively). Although the ART is superior for the determination of HCV RNA negativity, the predictive value of detectable HCV RNA for non-sustained virological response (non-SVR) by CAP/CTM is higher than by ART at weeks 4, 6, and 8. We also found that 16 (24.6%) by CAP/CTM and 28 (43.1%) by ART had a reappearance of residual HCV RNA during the telaprevir treatment period. However, the reappearance of residual HCV RNA was not associated with non-SVR. In conclusion, a significant difference was found between the two real-time PCR assays for the assessment of virological response based on undetectable HCV RNA.

UR - http://www.scopus.com/inward/record.url?scp=84880601180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880601180&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2013.05.002

DO - 10.1016/j.antiviral.2013.05.002

M3 - Article

C2 - 23684903

AN - SCOPUS:84880601180

VL - 99

SP - 119

EP - 124

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 2

ER -